MedTrace Logo

Single Agent Abraxane as Second Line Therapy in Bladder Cancer

NCT00683059 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2016-10-17

No results posted yet for this study

Summary

The purpose of this study is to determine what effects the drug Abraxane has on bladder cancer.

Conditions

  • Transitional Cell Carcinoma

Interventions

DRUG

Paclitaxel

total dose (mg) = body surface area in m2 x study dose (mg/m2) to be injected into a vein once every 3 weeks over 18 months.

Sponsors & Collaborators

  • Celgene Corporation

    collaborator INDUSTRY

  • Sunnybrook Health Sciences Centre

    lead OTHER

Principal Investigators

  • Yoo-Joung Ko, MD · Sunnybrook Health Sciences Centre

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00683059 on ClinicalTrials.gov